Roche delivers strong sales growth in the first nine months of 2017
- Group sales increase 5% at constant exchange rates and in Swiss francs
- Pharma: sales up 5%, driven mainly by Ocrevus, Tecentriq and Perjeta
- Diagnostics: sales grow 5%, primarily due to immunodiagnostics
- Outlook for 2017 confirmed
